PDF下载 ( 564 KB)
阻断HBV母婴传播： 热点与难点
DOI: 10.12449/JCH241102
利益冲突声明：本文不存在任何利益冲突。
作者贡献声明：尹雪如、洪睿轩负责文章撰写；刘志华负责文章审核；侯金林负责终审，并最终定稿。
Hotspots and challenges in blocking the mother-to-child transmission of hepatitis B virus
-
摘要: 慢性HBV感染是我国最重要的公共卫生问题之一，HBV感染人群超过7 000万，防控工作面临着严峻挑战。当前政府及社会各界正在加速推进“2030年实现消除病毒性肝炎对公众健康的威胁”的宏伟目标。母婴传播是HBV最主要的传播途径，因此，做好HBV母婴阻断是消除病毒性肝炎的关键一环。目前在该领域存在一些热点与难点问题亟需解决，包括妊娠期采用富马酸丙酚替诺福韦长期治疗的安全性、妊娠早期抗病毒治疗的安全性、无免疫球蛋白策略的有效性和HBV经生殖细胞传播的风险等，解决这些问题对进一步推进HBV母婴阻断工作，加快我国实现2030年目标的进程具有重要作用。
-
关键词:
- 乙型肝炎病毒 /
- 传染性疾病传播， 垂直 /
- 孕妇
Abstract: Chronic hepatitis B virus （HBV） infection remains a major public health challenge in China， affecting over 70 million people and posing great challenges to the prevention and control of the disease. At present， both the government and sectors of the society are making efforts to achieve the goal of eliminating viral hepatitis as a public health threat by 2030. Mother-to-child transmission is the main route of transmission of HBV， and therefore， blocking the mother-to-child transmission of HBV is the key link in eliminating viral hepatitis. At present， several critical issues still remain unresolved， including the long-term safety of tenofovir alafenamide fumarate during pregnancy， the safety of antiviral therapy in early pregnancy， the effectiveness of immunoglobulin-free strategy， and the risk of HBV transmission through germ cells. Addressing these challenges is important for promoting the blocking of the mother-to-child transmission of HBV and accelerating the progress toward the 2030 goals. -
百舸争流，奋楫者先。2023年，《临床肝胆病杂志》12期重点号专刊权威引领，树立学科发展风向标，奏响学术前沿最强音；创办“柳荫医学峰会”“柳芽医学论坛”“柳荫访谈”系列活动，打造我国医学学术活动品牌新IP；获准加入国际管理与技术编辑学会（ISMTE）和国际医学期刊编辑委员会（ICMJE），接轨国际学术出版规范之路取得新突破；数字出版矩阵建设从“相融”迈向“深融”，实现全媒体、全形态、全流程传播体系高速发展，官方网站年度访问量超236万次，21个新媒体平台年度受众超3 000万人次，79场学术直播参会观众超100万人。
笃行不怠，勇毅者胜。2023年，《临床肝胆病杂志》继续入编《中文核心期刊要目总览》；被荷兰《医学文摘（网络版）》（Embase）、ISSN国际中心开放学术资源库（ROAD）收录，稳居我国中文科技期刊进入国际知名数据库数量榜首；荣获“第四届吉林省高校科技期刊奖·卓越奖”；13篇论文入选中国科协“2023年度科技期刊双语传播工程”；2篇论文获评中华医学会“2023年度中华医学科技论文TOP100”；1篇论文荣膺中国科协“第八届优秀科技论文”，连续2届蝉联该奖项；在《科技期刊世界影响力指数（WJCI）报告》“消化病及腹部疾病”目录仅入选的8种中文期刊中排名四连冠；连续3届入选“中国精品科技期刊”，F5000论文入选总数（64篇）连续6年高居消化病学类精品科技期刊榜首；综合评价总分在我国消化病学类核心期刊中排名五连冠；近5年来第4次问鼎“百种中国杰出学术期刊”！
2023次列车已到站，2024号巨轮正启航。《临床肝胆病杂志》将继续凝专业之力，聚奋进之魂，夯学术之基，在新兴智能化信息革命中勇立潮头，以精品意识、精良内容、精准服务，助力我国肝胆病学科再创佳绩，更展新风！
岁且更始，时乃日新。恭祝大家新春嘉平！葳蕤繁祉！长乐未央！
《临床肝胆病杂志》主编 
2024年元月 -
[1] World Health Organization. Global health sector strategy on viral hepatitis 2016-2021[R]. Geneva: World Health Organization, 2016. [2] Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study[J]. Lancet Gastroenterol Hepatol, 2023, 8( 10): 879- 907. DOI: 10.1016/S2468-1253(23)00197-8. [3] LIANG XF, BI SL, YANG WZ, et al. Epidemiological serosurvey of hepatitis B in China: Declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27( 47): 6550- 6557. DOI: 10.1016/j.vaccine.2009.08.048. [4] Infectious Diseases Physicians Branch, Chinese Medical Doctor Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Chinese practice guideline for the prevention and treatment of mother-to-child transmission of hepatitis B virus(version 2024)[J]. J Clin Hepatol, 2024, 40( 8): 1557- 1566. DOI: 10.12449/JCH240809.中国医师协会感染科医师分会, 中华医学会感染病学分会. 中国乙型肝炎病毒母婴传播防治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 8): 1557- 1566. DOI: 10.12449/JCH240809. [5] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67( 2): 370- 398. DOI: 10.1016/j.jhep.2017.03.021. [6] TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67( 4): 1560- 1599. DOI: 10.1002/hep.29800. [7] Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. [8] PAN SF, ZHANG Y, ZENG YF, et al. Comparison of the efficacy and safety of TAF, TDF, and LdT to prevent the transmission of hepatitis B in pregnant women: A retrospective study[J]. Immun Inflamm Dis, 2024, 12( 2): e1204. DOI: 10.1002/iid3.1204. [9] ZENG QL, YU ZJ, JI F, et al. Tenofovir alafenamide to prevent perinatal hepatitis B transmission: A multicenter, prospective, observational study[J]. Clin Infect Dis, 2021, 73( 9): e3324- e3332. DOI: 10.1093/cid/ciaa1939. [10] DING Y, CAO LH, ZHU LY, et al. Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: A national cohort study[J]. Aliment Pharmacol Ther, 2020, 52( 8): 1377- 1386. DOI: 10.1111/apt.16043. [11] ZENG QL, ZHANG HX, ZHANG JY, et al. Tenofovir alafenamide for pregnant Chinese women with active chronic hepatitis B: A multicenter prospective study[J]. Clin Gastroenterol Hepatol, 2022, 20( 12): 2826- 2837. e 9. DOI: 10.1016/j.cgh.2021.12.012. [12] PREBOTH M. The antiretroviral pregnancy registry interim report[J]. Am Fam Physician, 2000, 61( 7): 2265. [13] CHEN RC, ZOU J, LONG LY, et al. Safety and efficacy of tenofovir alafenamide fumarate in early-middle pregnancy for mothers with chronic hepatitis B[J]. Front Med(Lausanne), 2022, 8: 796901. DOI: 10.3389/fmed.2021.796901. [14] YIN XR, HAN GR, ZHANG H, et al. A real-world prospective study of mother-to-child transmission of HBV in China using a mobile health application(shield 01)[J]. J Clin Transl Hepatol, 2020, 8( 1): 1- 8. DOI: 10.14218/JCTH.2019.00057. [15] YIN XR, WANG W, CHEN H, et al. Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China[J]. Nat Med, 2024, 30( 2): 455- 462. DOI: 10.1038/s41591-023-02782-x. [16] Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Clin Infect Dis, 2022, 15( 6): 401- 427. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.001.中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15( 6): 401- 427. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.001. [17] World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection[EB/OL].( 2024-03-29)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240090903. https://www.who.int/publications/i/item/9789240090903 [18] PAN CQ, DAI EH, YANG CL, et al. Tenofovir-df therapy prevents hepatitis B vertical transmission in highly viremic mothers without hbv immunoglobulin for infants[EB/OL].( 2022-10-21). https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.32697. DOI: 10.1002/hep.32697 [19] SEGERAL O, DIM B, DURIER C, et al. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia(TA-PROHM): A single-arm, multicentre, phase 4 trial[J]. Lancet Infect Dis, 2022, 22( 8): 1181- 1190. DOI: 10.1016/S1473-3099(22)00206-7. [20] SMITH K, SPADAFORA C. Sperm-mediated gene transfer: Applications and implications[J]. Bioessays, 2005, 27( 5): 551- 562. DOI: 10.1002/bies.20211. [21] SPADAFORA C. Sperm cells and foreign DNA: A controversial relation[J]. Bioessays, 1998, 20( 11): 955- 964. DOI:10.1002/(SICI)1521-1878(199811)20:11<955:AID-BIES11>3.0.CO;2-8. [22] SCIAMANNA I, VITULLO P, CURATOLO A, et al. Retrotransposons, reverse transcriptase and the genesis of new genetic information[J]. Gene, 2009, 448( 2): 180- 186. DOI: 10.1016/j.gene.2009.07.011. [23] PITTOGGI C, BERALDI R, SCIAMANNA I, et al. Generation of biologically active retro-genes upon interaction of mouse spermatozoa with exogenous DNA[J]. Mol Reprod Dev, 2006, 73( 10): 1239- 1246. DOI: 10.1002/mrd.20550. [24] BA ALI, HUANG TH, XIE QD. Detection and expression of hepatitis B virus X gene in one and two-cell embryos from golden Hamster oocytes in vitro fertilized with human spermatozoa carrying HBV DNA[J]. Mol Reprod Dev, 2005, 70( 1): 30- 36. DOI: 10.1002/mrd.20185. [25] ZHANG LY, FANG ZX, ZHENG Z, et al. Prelminary research on the paternal-fetal transmission of hepatitis b virus[J]. Chin J Infect Dis, 1994, 12( 4): 199- 201.张丽云, 方之勋, 郑兆, 等. 乙型肝炎病毒父婴传播途径的初步研究[J]. 中华传染病杂志, 1994, 12( 4): 199- 201. [26] YE F, YUE YF, LI SH, et al. Presence of HBsAg, HBcAg, and HBVDNA in ovary and ovum of the patients with chronic hepatitis B virus infection[J]. Am J Obstet Gynecol, 2006, 194( 2): 387- 392. DOI: 10.1016/j.ajog.2005.07.011. [27] NIE R, JIN L, ZHANG HW, et al. Presence of hepatitis B virus in oocytes and embryos: A risk of hepatitis B virus transmission during in vitro fertilization[J]. Fertil Steril, 2011, 95( 5): 1667- 1671. DOI: 10.1016/j.fertnstert.2010.12.043. [28] KONG Y, LIU Y, LIU XJ, et al. Relationship between the mechanism of hepatitis B virus father-infant transmission and pregnancy outcome[J]. Arch Gynecol Obstet, 2017, 295( 1): 253- 257. DOI: 10.1007/s00404-016-4231-6. [29] HUANG JM, HUANG TH, QIU HY, et al. Studies on the integration of hepatitis B virus DNA sequence in human sperm chromosomes[J]. Asian J Androl, 2002, 4( 3): 209- 212. [30] YI W, LI MH, SUN FF, et al. Impact of in vitro fertilization-embryo transfer on mother-to-infant transmission in women with chronic HBV infection[J]. Liver Int, 2022, 42( 10): 2167- 2174. DOI: 10.1111/liv.15349. [31] NIE R, WANG MY, LIAO TT, et al. Assisted conception does not increase the risk for mother-to-child transmission of hepatitis B virus, compared with natural conception: A prospective cohort study[J]. Fertil Steril, 2019, 111( 2): 348- 356. DOI: 10.1016/j.fertnstert.2018.10.021. -
本文二维码
计量
- 文章访问数: 394
- HTML全文浏览量: 1014
- PDF下载量: 104
- 被引次数: 0
下载:
